PeptidePedia The community reference

Talk:Cagrilintide

Discussion page·2 threads·no archives

This article is within the scope of the pharmacology working group.

This is the discussion page for the article Cagrilintide. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Calcitonin receptor engagementResolved

Worth stating that the calcitonin-receptor activity is real and its contribution unestablished, rather than omitting it because nothing is known. — CagriCass (talk) 09:40, 5 March 2026 (UTC)

It is the obvious candidate for any effect amylin pharmacology alone would not predict. ✓ Done — AmylinAmos (talk) 13:15, 5 March 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Aggregation and method coverageDone

A reverse-phase figure on an aggregation-prone peptide omits the attribute most likely to fail. Same point as at Amylin receptor agonist and worth repeating here. — StabilityStig (talk) 10:20, 29 May 2026 (UTC)

Repeated in its own terms rather than copied. ✓ Done — COA_Colwyn (talk) 13:55, 29 May 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 29 May 2026, by COA_Colwyn. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).